Resistell News:

Resistell AG closes CHF 3.5M series A financing round

newsimage
newsimage
Resistell News:

Resistell AG closes CHF 3.5M series A financing round

Resistell AG has today closed an oversubscribed series A financing round led by OCCIDENT. TRUMPF Venture, Alpana Ventures, Zürcher Kantonalbank, HEMEX and seven private investors also back the start-up developing world’s fastest phenotypic antibiotic susceptibility test.
curves

Latest news

news image news image
13th March 2019

Meet us it Berlin at Novel Antimicrobials and AMR Diagnostics 2019

We invite you to meet us in Berlin at Novel Antimicrobials & AMR Diagnostics Conference (14-15.03.2019). For more details please visit https://amr-conference.com
news image news image
27th December 2018

Resistell wins 3rd stage of VentureKick

The jury of industry experts and investors selected Resistell to receive the highest level of Venture Kick’s financial support to bring their businesses to market.
12th December 2018

Resistell closes the seed financing round

Resistell has closed an oversubscribed seed financing round. Lead Investor Occident Group AG, Hemex AG and six other private investors invested in the EPFL spin-off developing the world’s fastest phenotypic antibiotic susceptibility test.
11th November 2018

Resistell a finalist of the Swiss Technology Award 2018!

Resistell AG a finalist of the Swiss Technology Award 2018!
news image news image
1st November 2018

Resistell wins the MassChallenge Switzerland 2018 Gold Award

Resistell wins the MassChallenge Switzerland 2018 Gold Award
26th October 2018

Overuse of antibiotics 'risks return to dark ages of life-threatening surgery'

Warning comes as report shows 3 million common surgical procedures could be hazardous if infections become resistant to antibiotics
4th July 2018

Join us at the annual meeting of the SSM, 28-30 August.

Join us at the annual meeting of the Swiss Society for Microbiology held within the CHUV, Lausanne.